Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Summary
The Company intends to use the proceeds of the offering to fund the Companys ongoing activities, in connection with its planned investigational new drug (IND) filing for its proprietary patented injectable "local anesthetic" liposomal technology for post operative pain management (ProbudurTM), as well as for working capital and other general corporate purposes.Spartan Capital Securities, LLC is acting as the exclusive placement agent in connection with the offering.The offering is expected to close on November 14, 2024, subject to customary closing conditions. The offering is being conducted pursuant to the Companys registration statement on Form S-1, as amended (File No. Copies of the final prospectus relating to this offering, when available, may be obtained from Spartan Capital Securities, LLC, at 45 Broadway, 19th Floor, New York, NY 10006.This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance and optimize each product candidate in our pipeline. For more information, please visit https://www.virpaxpharma.com.Virpaxs shares of common stock trade on the Nasdaq Capital Market under the symbol "VRPX". Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue" or similar words.